Omidenepag isopropyl for the treatment of glaucoma and ocular hypertension

C. A. Cutolo, F. Barra, S. Ferrero, C. E. Traverso, Lorenzo Ferro Desideri

Research output: Contribution to journalArticlepeer-review


Glaucoma is a main cause of irreversible vision impairment and its prevalence is expected to rise significantly in the near future. Among the current medications, prostaglandin analogues (PGAs) are widely used and considered as a first-line strategy in the management of glaucoma and ocular hypertension (OHT). However, given the non-negligible incidence of adverse ocular effects (conjunctival hyperemia, increase of iris pigmentation and eyelash changes) due to the use of this class of drugs, novel PGAs are being investigated. Omidenepag isopropyl is a selective prostaglandin EP2 receptor agonist which was approved on September 21, 2018, in Japan for the treatment of glaucoma and OHT. In this review, we will discuss its pharmacokinetics, pharmacodynam-ics and clinical efficacy, focusing also on its safety and tolerability profile.

Original languageEnglish
Pages (from-to)377-384
Number of pages8
JournalDrugs of Today
Issue number6
Publication statusPublished - Jan 1 2019


  • Antiglaucoma agents
  • Eye disorders
  • Glaucoma
  • Ocular hypertension
  • Omidenepag isopropyl
  • Ophthalmic drugs

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Omidenepag isopropyl for the treatment of glaucoma and ocular hypertension'. Together they form a unique fingerprint.

Cite this